Galderma Announces ‘Positive Results’ with New 6-Month Wrinkle Relaxing Injectable


The next generation of wrinkle relaxers are coming soon and Galderma, the company that makes Dysport, just announced the positive outcomes they’ve seen with RelabotulinumtoxinA, a liquid neurotoxin that treats glabellar lines and crow’s feet. In two studies done during clinical trials, the new toxin has been shown to last months longer than botulinum toxin treatments available now.

It Doesn’t Have to Be Mixed

The new injectable isn’t available to consumers yet, but here’s what we know so far: At the Vegas Cosmetic Surgery & Aesthetic Dermatology meeting last week the company released the findings of two studies that showed the participants who received the treatment experienced results in as little as two days, with results lasting up to six months. Unlike botulinum toxin products on the market now that come in powder forms, RelabotulinumtoxinA is ready-to-use liquid botulinum toxin A, which Galderma says eliminates any “variability, errors and risks” associated with mixing and reconstituting the powder formulation.

“Galderma’s newest botulinum toxin A, RelaabotulinumtoxinA, has several features which make it interesting,” shares Greenwich, CT, dermatologist Lynne Haven, MD. “First, it comes from the company in liquid form so it is ready to inject right away and does not have to be reconstituted. Second, the early data from the phase 3 clinical trials show a quick onset of action at two days and good longevity data lasting up to six months.”

Longer-Lasting Results

“We developed this innovative neuromodulator to respond directly to the needs of healthcare professionals and the expectations of patients who are looking for a safe, effective, long-lasting treatment that offers consistency in results for frown lines and crow’s feet, which can have a significant impact on patients’ self-esteem and well-being,” said Galderma’s global head of research and development, Baldo Scassellati Sforzolini, MD. “We are looking forward to submitting the data to U.S. and global authorities as part of the next step in bringing this potential, new treatment to patients.”

What to Expect

Galderma’s RelabotulinumtoxinA is in phase three of clinical trials which means that it will soon be able to seek FDA approval. The studies in this phase “met their primary endpoint, demonstrating a significant ≥2-grade composite improvement in glabellar line severity and lateral canthal line severity vs. placebo at Month 1, with rapid onset of action and up to six-month duration of action,” the company shared in a press release.

“The early data on Galderma’s new neurotoxin seems extremely promising,” says Wayne, NJ facial plastic surgeon Jeffrey B. Wise, MD. “The possibility of a more rapid onset and longer duration will potentially set it apart from the current neuromodulators on the US market.  I look forward to this potentially game-changing neurotoxin.”

While we don’t have specifics on when exactly it will be hitting the market, we do know that it’s another sign that the next generation of wrinkle relaxers are here and it’s just a matter of time before we’re able to test them out ourselves.

Find a Doctor

Find a NewBeauty “Top Beauty Doctor” Near you












Credit: Source link

Discover

19,463FansLike
232,230FollowersFollow
77,986FollowersFollow
13,853FollowersFollow
2,920SubscribersSubscribe

Sponsor

spot_imgspot_img

Latest

Fall Fashion Trends To Get Excited About

Fall 2022 is shaping up to be an amazing season.We’re already getting hints that there will be a blend of the athleisure-inspired comfort...

Serena Pitt Shares Her Secrets to Nailing No-Makeup Makeup—and the Skin Care She Shares with Joe Amabile

You probably fell in love with Serena Pitt on season 25 of The Bachelor or season seven of Bachelor in Paradise, just...

Maren Morris Won’t Attend Late Night Dinners After Becoming a Mom

Count her out! Maren Morris opened up about being a mom to 2-year-old son Hayes — and why she will no longer be...

In Just 7 Words, the British Prime Minister Taught Every CEO How Not to Communicate in a Crisis

After a controversial tax policy that created ten days of market carnage, the newly-appointed British Prime Minister claimed, "It was a decision the...

Should You Be Eating For Your Blood Type?

In 1996, naturopathic physician Dr. Peter J. D’Adamo wrote The New York Times best-seller Eat Right 4 Your Type, which is based...
en English
X